Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization

  • Proc Natl Acad Sci U S A. 2023 Jan 31;120(5):e2208960120. doi: 10.1073/pnas.2208960120.
Lucy C Young  1 Ruby Goldstein de Salazar  1 Sae-Won Han  2 Zi Yi Stephanie Huang  1 Alan Merk  3 Matthew Drew  4 Joseph Darling  3 Vanessa Wall  4 Reinhard Grisshammer  3 Alice Cheng  1 Madeline R Allison  1 Matthew J Sale  1 Dwight V Nissley  4 Dominic Esposito  4 Jana Ognjenovic  3 Frank McCormick  1
Affiliations
  • 1. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94153.
  • 2. Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea.
  • 3. National Cryo-EM Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
  • 4. National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
Abstract

The majority of pathogenic mutations in the neurofibromatosis type I (NF1) gene reduce total neurofibromin protein expression through premature truncation or microdeletion, but it is less well understood how loss-of-function missense variants drive NF1 disease. We have found that patient variants in codons 844 to 848, which correlate with a severe phenotype, cause protein instability and exert an additional dominant-negative action whereby wild-type neurofibromin also becomes destabilized through protein dimerization. We have used our neurofibromin cryogenic electron microscopy structure to predict and validate Other patient variants that act through a similar mechanism. This provides a foundation for understanding genotype-phenotype correlations and has important implications for patient counseling, disease management, and therapeutics.

Keywords
NFI; cryo-EM; neurofibromatosis type I.
Products